✦ LIBER ✦

PCN111 Evaluating Meaningful Change on the Lung Cancer Symptom Scale in Small Cell Lung Cancer: Results From a Phase III Clinical Trial

✍ Scribed by O'Brien, M.; Hudgens, S.; King, J.; McNally, R.; Khan, Z.

Book ID: 122145059
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 71 KB
Volume: 15
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2012.03.1228

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN141 Quality of Life in Small Cell Lun

PCN141 Quality of Life in Small Cell Lung Cancer: Results of an Open-Label Phase III Clinical Trial

✍ Hudgens, S.; King, J.; Khan, Z.M. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

The Clinical Development of Vandetanib:

The Clinical Development of Vandetanib: Updates on Ongoing Phase III Clinical Trials in Advanced Non—Small-Cell Lung Cancer

✍ John Heymach 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 70 KB

Economic evaluation in a randomized phas

Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer

✍ Sacristán, J 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 110 KB

O-235 Accommodating prior beliefs in the

O-235 Accommodating prior beliefs in the analysis of phase III clinical trials: A bayesian view on results from trials of chemotherapy in non-small cell lung cancer

✍ Billingham, Lucinda J.; Cullen, Michael 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

Phase III Study of Erlotinib in Combinat

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

✍ Gatzemeier, U.; Pluzanska, A.; Szczesna, A.; Kaukel, E.; Roubec, J.; De Rosa, F. 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 169 KB

## Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of chemotherapy. This phase III, randomized, double-blind, placebo-controlled, multicenter trial evaluated th